New drug tested for Hard-to-Treat lung blood pressure disease
NCT ID NCT05679570
Summary
This study is testing whether a drug called satralizumab can help patients with pulmonary arterial hypertension (PAH) who haven't responded well to current treatments. It will involve about 20 patients in Japan who have a specific immune-related profile. The main goal is to see if the drug reduces resistance in the lung's blood vessels and improves how far patients can walk over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiba University Hospital
Chiba, 260-8677, Japan
-
Hokkaido University Hospital
Sapporo, 060-8648, Japan
-
International University of Health and Welfare Mita Hospital
Tokyo, 108-8329, Japan
-
Kagoshima University Hospital
Kagoshima, Kagoshima-ken, 890-8520, Japan
-
Kobe University Hospital
Kobe, 650-0017, Japan
-
Kurume University Hospital
Kurume, 830-0011, Japan
-
Kyorin University Hospital
Mitaka, 181-8611, Japan
-
Kyushu University Hospital
Fukuoka, 812-8582, Japan
-
Nagoya University Hospital
Nagoya, 466-8560, Japan
Conditions
Explore the condition pages connected to this study.